ZARXIO reduces the risk of infection1
Why was ZARXIO prescribed for me?
Some cancer treatments decrease white blood cell counts (which may result in a condition called neutropenia), increasing the risk of infection. ZARXIO is a prescription medication used to reduce the risk of infection in patients with some tumors who are receiving strong chemotherapy that may cause severe neutropenia with fever.1,2
What is a biosimilar?
A biosimilar is a medication that has been approved by the FDA as being “highly similar” to a previously approved biologic medication. Biosimilars may be available at a lower cost than the referenced biologic medication. ZARXIO is the first biosimilar approved in the US.3-5
HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241718.htm. Accessed May 3, 2017. 4. US Food and Drug Administration. Fact sheet: new "biosimilars" user fees will enhance Americans' access to alternatives to biologic drugs. http://www.fda.gov/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/ucm311121.htm. Accessed May 3, 2017. 5. FDA approves first biosimilar product Zarxio [press release]. US Food and Drug Administration; March 6, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm. Accessed May 3, 2017.
ZARXIO is a registered trademark of Novartis AG.